Should treatment of low-level rifampicin mono-resistant tuberculosis be different? by Armand Van Deun, Tom Decroo

Get full text

Roles of laboratories and laboratory systems in effective tuberculosis programmes by John C Ridderhof, Armand van Deun, Kai Man Kam, PR Narayanan, Mohamed Abdul Aziz

Get full text

GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis by Leen Rigouts, Jelle Keysers, Reenaers Rabab, Kristina Fissette, Armand van Deun, Bouke Catherine de Jong

Get full text

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide by Géraldine Daneau, Mourad Gumusboga, Pim De Rijk, Arnaud Trebucq, Leen Rigouts, Armand Van Deun, Bouke C de Jong

Get full text

Multi drug resistant tuberculosis in Mosango, a rural area in the Democratic Republic of Congo. by Michel Kayomo Kaswa, Serge Bisuta, Georges Kabuya, Octavie Lunguya, André Ndongosieme, Jean Jacques Muyembe, Armand Van Deun, Marleen Boelaert

Get full text

Management of falsepositive rifampicin resistant Xpert MTB/RIF – Authors' reply by Jean Claude Semuto Ngabonziza, Tom Decroo, Gabriela Torrea, Patrick Migambi, Armand Van Deun, Leen Rigouts, Bouke Catherine de Jong

Get full text

Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. by Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Cécile Uwizeye, Mourad Gumusboga, Tine Demeulenaere, Nimer Ortuño-Gutiérrez, Bouke C de Jong, Armand Van Deun

Get full text

High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin by Mahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, Achilleas Tsoumanis, Alphazazi Soumana, Hamidou Issa, Abdoulaziz Kabirou Amoussa, Armand Van Deun, Lutgarde Lynen, Bouke Catherine de Jong, Tom Decroo

Get full text

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. by Armand Van Deun, Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Murid Gumusboga, Wim Mulders, Nimer Ortuño-Gutiérrez, Lutgarde Lynen, Bouke C de Jong, Hans L Rieder

Get full text

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic rand... by Mahamadou Bassirou Souleymane, Tom Decroo, Alphazazi Soumana, Ibrahim Maman Lawan, Assiatou Gagara-Issoufou, Souleymane Halidou-Moussa, Nimer Ortuño-Gutiérrez, Eric Adehossi, Saïdou Mamadou, Armand Van Deun, Alberto Piubello

Get full text

Worldwide Emergence of Extensively Drug-resistant Tuberculosis by N. Sarita Shah, Abigail Wright, Gill-Han Bai, Lucia Barrera, Fadila Boulahbal, Nuria Martín-Casabona, Francis Drobniewski, Chris Gilpin, Marta Havelková, Rosario Lepe, Richard Lumb, Beverly Metchock, Françoise Portaels, Maria Filomena Rodrigues, Sabine Rüsch-Gerdes, Armand Van Deun, Veronique Vincent, Kayla F. Laserson, Charles Wells, J. Peter Cegielski

Get full text

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda by Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD

Get full text